# A Study of ANAVEX3-71 in Adults With Schizophrenia

> **NCT06245213** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Anavex Life Sciences Corp.** · enrollment: 71 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ANAVEX3-71 oral capsules
- **DRUG:** Placebo oral capsules

## Key facts

- **NCT ID:** NCT06245213
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245213, "A Study of ANAVEX3-71 in Adults With Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06245213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*